Table 2.
Clinical features of PTMC and non-PTMC
| Variable | PTMC (≤1 cm, n=83) | Non-PTMC (>1 cm, n=67) | P-value |
|---|---|---|---|
| Age (yr) | 68.7±3.3 | 70.2±4.9 | 0.025 |
| Female sex | 66 (79.5) | 55 (82.1) | 0.836 |
| Size (cm) | 0.6±0.2 | 2.3±1.6 | <0.001 |
| Number | 1.4±0.7 | 1.5±0.8 | 0.472 |
| Multiplicity | 29 (34.9) | 24 (35.8) | >0.990 |
| Total thyroidectomy | 64 (77.1) | 59 (88.1) | 0.127 |
| RAIT (%) | 30 (36.1) | 53 (79.1) | <0.001 |
| Dose of RAIT (mCi) | 37.6±54.8 | 104.2±59.8 | <0.001 |
| ETE | 15 (25.9) | 43 (74.1) | <0.001 |
| Minimal extension | 15 (25.9) | 35 (52.2) | 0.014 |
| Wide invasion | 0 | 8 (11.9) | <0.001 |
| LNM | 23 (27.7) | 40 (59.7) | <0.001 |
| Central LNM | 23 (27.7) | 35 (52.2) | 0.003 |
| Lateral LNM | 4 (4.8) | 8 (11.9) | 0.195 |
| Recurrence | 2 (2.7) | 15 (24.2) | <0.001 |
| Follow-up period (mo) | 43.5±28.1 | 43.6±29.4 | 0.985 |
Values are presented as mean±SD or number (%).
PTMC, papillary thyroid microcarcinoma (largest diameter of the tumor ≤1 cm); non-PTMC, non-papillary thyroid microcarcinoma (largest diameter of the tumor >1 cm); RAIT, radioactive iodine therapy; ETE, extrathyroidal extension; LNM, lymph node metastasis.